Diligence memo · auto-generated · as of July 2, 2026
Nektar Therapeutics
Nektar Therapeutics has raised $880M over 2 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Nektar Therapeutics operates in Pharmaceuticals, based in San Francisco.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nektar Therapeutics has raised $880M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $850M on 2018-04-03.
Most recent recorded round closed around 2024-03-04.
Valuation (modeled)modeled
Provath models Nektar Therapeutics at approximately $417M (range $197M–$548M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 71 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 28.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: Bicycle Therapeutics Plc.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.